ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
An Implantable Microstimulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects (BBPM)

This study is currently recruiting participants.
Study NCT00567541.   Last updated on June 19, 2008.   Information provided by Bioness Inc

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  An Implantable Microstimulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects
Official Title  Feasibility Study of the Bioness Battery-Powered Microstimulator (BBPM) to Treat Chronic Shoulder Pain in Chronic Post-Stroke Subjects
Brief Summary

The goal of this research study is to investigate the safety and effectiveness of a new implanted device designed to treat chronic shoulder pain in chronic post-stroke subjects. The BBPM weighs less than 0.03 ounces and measures 1" x 0.1". It is implanted into the shoulder to stimulate the axillary nerve. Stimulation of this nerve may reduce shoulder pain, reduce shoulder subluxation, improve motion, improve function, and decrease use of pain medication. CAUTION--Investigational device. Limited by Federal law to investigational use.

Detailed Description

This is a prospective, dual-center, randomized, controlled, double-blinded parallel study designed to evaluate the feasibility and safety of using the The primary purpose of this study is to demonstrate the clinical feasibility of implanting the BBPM near a peripheral nerve for the treatment of chronic, intractable, pain in this case represented by chronic regional shoulder pain in hemiplegic stroke patients. This is a 48-week study with a two-year follow up.

Study Phase Phase II
Study Type  Interventional
Study Design  Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary Outcome Measure  The primary outcome measure will be the feasibility of using the BBPM for treatment of chronic shoulder pain as evidenced by appropriate muscular contraction and/or paresthesias with no significant adverse events. [ Time Frame: From baseline to follow up ] [ Designated as safety issue: Yes ]
Secondary Outcome Measure  Greater than 30% Pain Reduction measured by using Brief Pain Inventory (BPI #12) at each time point without increasing pain medication -Range of motion will be quantified using a goniometer -Motor functions will be measured by Fugl-Meyer Test [ Time Frame: From baseline to follow-up ] [ Designated as safety issue: No ]
Range of Motion: pain-free passive shoulder abduction, flexion and external rotation will be quantified. [ Time Frame: baseline to end of study ] [ Designated as safety issue: No ]
-Interference of shoulder pain in daily activities and function measured by using BPI#23 -Quality of Life assessed by using he EuroQol -Reported use of pain medication -Examined for shoulder subluxation -Examined for cutaneous shoulder sensation [ Time Frame: baseline to end of study ] [ Designated as safety issue: Yes ]
Condition  Chronic Shoulder Pain in Chronic Post-Stroke
Intervention  Device: Bioness Battery Powered Microstimulator
Device: Battery-Powered Microstimulator (BBPM)
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  16
Start Date  June 2007
Completion Date December 2009
Eligibility Criteria 

Inclusion Criteria:

  • 18 years of age or older
  • Chronic post-stroke duration greater than or equal to 6 months
  • Unilateral hemiplegic shoulder pain persisting for ≥6 months
  • Hemiparesis (shoulder abduction graded <5/5 on Manual Muscle Testing ipsilateral to the shoulder in which the subject has chronic pain
  • Shoulder pain ≥ 6/10 (on 0-10 numeric rating scale (NRS) for worst pain in last week (BPI #12))
  • Ability to give informed consent and understand study requirements
  • Ability to quantify pain using a 0-10 numeric rating scale. (A screening tool will be used to ensure that participants can rate 3 common pain scenarios (mosquito bite, stubbed toe and broken bone) on a 0-10 NRS relative to each other.)
  • Willing and able to understand and comply with all study-related procedures during the course of the study
  • Motivated to maintain an accurate diary for the study duration

Exclusion Criteria:

  • Hemineglect (i.e., extinguish to double simultaneous stimulation)
  • Shoulder trauma or diagnosed shoulder pathology prior to stroke; history of any shoulder surgery, regardless of whether procedure preceded for followed stroke.
  • Need to take >1 pain medication (opioid or non-opioid) for shoulder pain
  • Regular use of pain medication for chronic pain other than shoulder pain
  • Anticoagulated (taking warfarin or heparin, including fractionated heparin) or has a bleeding disorder
  • Unable, per their prescribing physician, to stop antiplatelet medications (e.g., aspirin, ticlopidine (Ticlid), clopidogrel (Plavix), tirofiban (Aggrastat), and eptifibatide (Integrilin)) for at least 7 days prior to device implantation.
  • Cardiac pacemaker
  • Implanted neurostimulator (e.g., spinal cord, deep brain, vagus nerve) or implanted pump or infusion device
  • Prosthetic heart valve or valvular heart disease requiring antibiotic prophylaxis
  • History of cardiac arrhythmia with hemodynamic instability
  • Uncontrolled seizures (> 1 seizure per month)
  • Pregnant or plan on becoming pregnant during the study period
  • Medical instability
  • Currently require, or likely to require, diathermy
  • Currently require, or anticipated to require, MRI within 8 weeks of projected device implantation date
  • History of adverse reactions to local anesthetic (e.g., lidocaine)
Gender Both
Ages 18 Years to 85 Years
Accepts Healthy Volunteers No
Contacts ††
Contact: Charina Icamen-Curry     (661) 362-6646     charina.icamencurry@bioness.com    
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00567541
Organization ID CP-BBPM-001
Secondary IDs ††
Study Sponsor  Bioness Inc
Collaborators ††
Investigators 
Study Director:     Evan Rosenfeld, MD, JD     Bioness Inc    
Principal Investigator:     Andrew Friedman, MD     Virginia Mason Seattle Main Clinic    
Principal Investigator:     Tim Deer, MD     The Center for Pain Relief    
Information Provided By Bioness Inc
Verification Date June 2008
First Received Date  December 3, 2007
Last Updated Date June 19, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers